News >

Hurvitz Highlights Advances in HER2+ Breast Cancer Treatment

Brandon Scalea
Published: Monday, Aug 06, 2018

Sara A. Hurvitz, MD

Sara A. Hurvitz, MD

Historically, a diagnosis of HER2-positive breast cancer left a patient with a grim outlook, but therapeutic advances over the past 10 to 15 years have dramatically altered the landscape, explained Sara A. Hurvitz, MD.

, Hurvitz discussed targeted therapy advancements, the rise of trastuzumab biosimilars, and the future of HER2-positive breast cancer treatment.

OncLive: How have HER2-targeted therapies improved outcomes for patients with this breast cancer subtype?

Hurvitz: It has literally altered the natural history of this disease; without HER2-targeted therapies, it has among the worst prognoses. There are new therapies that have been FDA approved over the last 1.5 years or so. Neratinib is approved for 1 year after completing trastuzumab and chemotherapy. Pertuzumab is approved for 1 year given concurrently with trastuzumab. Figuring out who to use these agents for is a bit tricky.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication